{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:40:05Z","timestamp":1758739205936,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NIAID","award":["R25:1R25AI147375"],"award-info":[{"award-number":["R25:1R25AI147375"]}]},{"name":"NIH\/NIAID","award":["P30:P30AI168440"],"award-info":[{"award-number":["P30:P30AI168440"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The optimal duration of antibiotic treatment must strike a delicate balance: it must be long enough to achieve desirable efficacy yet short enough to prevent the development of toxicities, adverse events, and mitigate other arduous aspects related to patient burden. Historically, the approach used to determine duration of antibiotic treatment has been inefficient, severely impacting the refinement of therapeutics for tuberculosis (TB) where treatment duration, and its complications, can be extensive. Many of the challenges in duration-ranging have parallels and proposed solutions in the field of dose-ranging where the literature is substantially more established and where the traditions of qualitative, pairwise comparison studies have been replaced with model-based approaches. Such methods are more efficient and allow for interpolation between the doses observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This work examines the utility of cutting-edge dose-finding methods (such as MCP-Mod) for duration-ranging of TB treatments. We compare the operating characteristics of the adapted model-based duration-ranging methodologies against standard qualitative methods for the purposes of estimating optimal duration and describing the duration-response relationship, using a simulation study motivated by a Multi-Arm Multi-Stage Response Over Continuous Intervention (MAMS-ROCI) clinical trial design. We explore three specific targets: (1) power to detect a duration-response relationship, (2) ability to accurately reproduce the duration-response curve, and (3) ability to estimate the optimal duration within an acceptable margin of error.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We find that model-based methods outperform standard qualitative comparisons on every target examined, particularly when the sample size is constrained to that of a typical Phase II trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We conclude that the success of the next era in TB therapeutics duration evaluation trials, and antibiotics duration-ranging more broadly, will meaningfully rely on the ability to simultaneously pair innovative model-based statistical methods with re-imagined study designs such as MAMS-ROCI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-09050-y","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:14:31Z","timestamp":1758737671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of methods for identifying the optimal treatment duration in randomized trials for antibiotics"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-6548","authenticated-orcid":false,"given":"Suzanne M.","family":"Dufault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian H.","family":"Aldana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"9050_CR1","volume-title":"Global Tuberculosis Report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023."},{"key":"9050_CR2","unstructured":"NIAID Tuberculosis Research Strategic Plan Working Group. NIAID Strategic Plan for Tuberculosis Research. 2019."},{"issue":"9","key":"9050_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1164\/rccm.202101-0117OC","volume":"204","author":"MZ Imperial","year":"2021","unstructured":"Imperial MZ, Phillips PJ, Nahid P, Savic RM. Precision-enhancing risk stratification tools for selecting optimal treatment durations in tuberculosis clinical trials. Am J Respir Crit Care Med. 2021;204(9):1086\u201396.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"9050_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/1740774518778027","volume":"15","author":"M Quartagno","year":"2018","unstructured":"Quartagno M, Walker AS, Carpenter JR, Phillips PPJ, Parmar MKB. Rethinking non-inferiority: a practical trial design for optimising treatment duration. Clin Trials. 2018;15(5):477\u201388.","journal-title":"Clin Trials"},{"key":"9050_CR5","unstructured":"Working Group for New TB Drugs. Clinical pipeline [Internet]. 2024 [cited 2025 Apr 14]. https:\/\/www.newtbdrugs.org\/pipeline\/clinical.\u00a0Accessed 2 July 2024."},{"issue":"1","key":"9050_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-14-88","volume":"14","author":"CR Horsburgh","year":"2013","unstructured":"Horsburgh CR, Shea KM, Phillips P, LaValley M. Randomized clinical trials to identify optimal antibiotic treatment duration. Trials. 2013;14(1): 88.","journal-title":"Trials"},{"issue":"17","key":"9050_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577\u201387.","journal-title":"N Engl J Med"},{"issue":"7","key":"9050_CR8","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1128\/AAC.00105-15","volume":"59","author":"S-Y Li","year":"2015","unstructured":"Li S-Y, Irwin SM, Converse PJ, et al. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015;59(7):4026\u201330.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"9050_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332.","journal-title":"N Engl J Med"},{"key":"9050_CR10","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. 2022."},{"issue":"4","key":"9050_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/bimj.200810438","volume":"50","author":"F Bretz","year":"2008","unstructured":"Bretz F, Hsu J, Pinheiro J, Liu Y. Dose finding\u2013a challenge in statistics. Biom J. 2008;50(4):480\u2013504.","journal-title":"Biom J"},{"issue":"22","key":"9050_CR12","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1002\/sim.6991","volume":"35","author":"K Schorning","year":"2016","unstructured":"Schorning K, Bornkamp B, Bretz F, Dette H. Model selection versus model averaging in dose finding studies. Stat Med. 2016;35(22):4021\u201340.","journal-title":"Stat Med."},{"issue":"6","key":"9050_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/10543400701643848","volume":"17","author":"B Bornkamp","year":"2007","unstructured":"Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17(6):965\u201395.","journal-title":"J Biopharm Stat"},{"issue":"5","key":"9050_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/10543400600860469","volume":"16","author":"N Thomas","year":"2006","unstructured":"Thomas N. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs. J Biopharm Stat. 2006;16(5):657\u201377.","journal-title":"J Biopharm Stat"},{"issue":"3","key":"9050_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","volume":"61","author":"F Bretz","year":"2005","unstructured":"Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005;61(3):738\u201348.","journal-title":"Biometrics"},{"key":"9050_CR16","unstructured":"USA Food and Drug Administration. Statistical review and evaluation qualification of statistical approach: MCP-Mod. 2016."},{"key":"9050_CR17","unstructured":"European Medicines Agency. Qualification opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty. 2014."},{"issue":"11","key":"9050_CR18","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/sim.8086","volume":"38","author":"TP Morris","year":"2019","unstructured":"Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Stat Med. 2019;38(11):2074\u2013102.","journal-title":"Stat Med"},{"issue":"7","key":"9050_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v029.i07","volume":"29","author":"B Bornkamp","year":"2009","unstructured":"Bornkamp B, Pinheiro J, Bretz F. MCPmod: an R package for the design and analysis of dose-finding studies. J Stat Softw. 2009;29(7):1\u201323.","journal-title":"J Stat Softw"},{"issue":"10","key":"9050_CR20","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/sim.6052","volume":"33","author":"J Pinheiro","year":"2014","unstructured":"Pinheiro J, Bornkamp B, Glimm E, Bretz F. Model-based dose finding under model uncertainty using general parametric models. Stat Med. 2014;33(10):1646\u201361.","journal-title":"Stat Med"},{"key":"9050_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2330","author":"F Liu","year":"2023","unstructured":"Liu F, Zhao Q, Rodgers AJ, Mehrotra DV. Calculation of phase 2 dose-finding study sample size for reliable phase 3 dose selection. Pharm Stat. 2023. https:\/\/doi.org\/10.1002\/pst.2330.","journal-title":"Pharm Stat"},{"issue":"6","key":"9050_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/1740774520944377","volume":"17","author":"M Quartagno","year":"2020","unstructured":"Quartagno M, Carpenter JR, Walker AS, Clements M, Parmar MKB. The DURATIONS randomised trial design: estimation targets, analysis methods and operating characteristics. Clin Trials. 2020;17(6):644\u201353.","journal-title":"Clin Trials"},{"key":"9050_CR23","unstructured":"Bornkamp B, Pinheiro J, Bretz F, Sandig L. DoseFinding: Planning and Analyzing Dose Finding Experiments [Internet]. Version 1.0-2. 2021 [cited 2025 Apr 14]. https:\/\/CRAN.R-project.org\/package=DoseFinding."},{"key":"9050_CR24","doi-asserted-by":"crossref","unstructured":"Bojanowski M. lspline: Linear Splines with Convenient Parametrisations [Internet]. Version 1.0-0. 2017 [cited 2025 Apr 14]. https:\/\/CRAN.R-project.org\/package=lspline.","DOI":"10.32614\/CRAN.package.lspline"},{"issue":"3","key":"9050_CR25","first-page":"507","volume":"54","author":"RA Rigby","year":"2005","unstructured":"Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and shape (with discussion). Appl Stat. 2005;54(3):507\u201354.","journal-title":"Appl Stat"},{"key":"9050_CR26","unstructured":"Signorell A. DescTools: Tools for Descriptive Statistics [Internet]. Version 0.99.50. 2023 [cited 2025 Apr 14]. https:\/\/CRAN.R-project.org\/package=DescTools."},{"issue":"43","key":"9050_CR27","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43): 1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Source Softw"},{"key":"9050_CR28","unstructured":"Pedersen TL. patchwork: The Composer of Plots [Internet]. Version 1.1.1. 2020 [cited 2025 Apr 14]. https:\/\/CRAN.R-project.org\/package=patchwork."},{"key":"9050_CR29","doi-asserted-by":"crossref","unstructured":"Pham TM, Crook AM, Rolfe K, Phillips PPJ, Dufault SM, Quartagno M. Designing a response-over-continuous-interventions (ROCI) randomised trial: Implementation in the phase 2C part (duration ranging) of the PARADIGM4TB trial. Contemporary Clinical Trials. Elsevier BV; 2025;108002. https:\/\/doi.org\/10.1016\/j.cct.2025.108002.","DOI":"10.1016\/j.cct.2025.108002"},{"issue":"7","key":"9050_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/psp4.12196","volume":"6","author":"FT Musuamba","year":"2017","unstructured":"Musuamba FT, Manolis E, Holford N, et al. Advanced methods for dose and regimen finding during drug development: summary of the EMA\/EFPIA workshop on dose finding (London 4\u20135 December 2014). CPT Pharmacometrics Syst Pharmacol. 2017;6(7):418\u201329.","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09050-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09050-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09050-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:14:33Z","timestamp":1758737673000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09050-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9050"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09050-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"352"}}